Operating performance
Revenue, profitability, and free cash flow are shown together so you can see scale, margin conversion, and cash generation on one screen.
Annualised change across the filed history.
Revenue CAGR 5Y
11.6%
Operating Income CAGR 3Y
36.5%
Filing-backed read on scale, margins, and cash flow.
Free Cash Flow
FY 2025+48.7%
Net Margin
FY 2025-4.1 pt
Valuation snapshot
A target is published only when both the filing-backed DCF and the peer fair value clear the confidence gate.
Current price
—
Market cap —
Fair value estimate
Withheld
Peer breadth and filing-backed DCF both failed the evidence gate.
Implied upside
—
Peers: 6 usable peers from 6 saved peers with 0 active peer methods. Need at least 2 usable SEC-backed peers for fallback target coverage. DCF: Debt and bridge-cash inputs are required to translate enterprise value into equity value.
This score describes input coverage, not the probability that a valuation or investment return will be correct.
Evidence gate detail
Peer breadth and filing-backed DCF both failed the evidence gate.
Peers: 6 usable peers from 6 saved peers with 0 active peer methods. Need at least 2 usable SEC-backed peers for fallback target coverage. DCF: Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Policy
Filing-Backed v2
Basis
Operating cash flow less capex (firm-value proxy)
Shares
Diluted shares
Bridge
Net debt + securities
Market context
Market price unavailable
Current price stacked against the same public-equity anchors shown in the confidence-gated hero.
How to read this
Capital structure
The overview keeps the capital structure bridge close to the cash-generation picture so fair value can be read in equity terms.
FY 2025 · filed Feb 26, 2026
Cash & Securities
$1.3B
Total Debt
—
Net Cash / Debt
—
Equity
Peer context
The overview keeps peer evidence concise here and sends detailed bridging to the relative-valuation tab.
Peer fair value
Per-share fair value from the weighted peer set.
Average P/E
Price to earnings across covered peers.
Average P/S
Price to sales across covered peers.
Intrinsic context
The overview surfaces the baseline intrinsic read and the reverse-DCF question, then sends the deeper workbench to the intrinsic tab.
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Company profile
Identifiers, classification, and listing detail behind every figure on this page.
$6.1B
Tangible Equity
$5.7B
Net cash or debt is unavailable because complete debt and cash evidence is required to bridge enterprise value into equity value.
Latest annual cash generation after capital spending.
Operating Cash Flow
$828M
Capital Expenditures
$-103M
Free Cash Flow
$725M
CFO Margin
25.7%
FCF Margin
22.5%
CFO / Net Income
2.37x
FCF / Net Income
2.08x
Quality and risk
Altman, Piotroski, liquidity, and leverage sit together so the valuation read can be judged against balance-sheet reality.
Distress risk from the latest annual balance sheet.
Nine filing-backed checks on profitability, leverage, and efficiency.
neutral
Current Ratio
5.21x
Quick Ratio
3.50x
Average EV/EBITDA
Enterprise multiple across covered peers.
6 peers across 0 active peer methods
VERTEX PHARMACEUTICALS INC / MA
VRTX · CIK 0000875320
—
—
—
—
Cap —P/E —EV/EBITDA —
ALNYLAM PHARMACEUTICALS, INC.
ALNY · CIK 0001178670
—
—
—
—
Cap —P/E —EV/EBITDA —
Sarepta Therapeutics, Inc.
SRPT · CIK 0000873303
—
—
—
—
Cap —P/E —EV/EBITDA —
REGENXBIO Inc.
RGNX · CIK 0001590877
—
—
—
—
Cap —P/E —EV/EBITDA —
IONIS PHARMACEUTICALS INC
IONS · CIK 0000874015
—
—
—
—
Cap —P/E —EV/EBITDA —
PTC THERAPEUTICS, INC.
PTCT · CIK 0001070081
—
—
—
—
Cap —P/E —EV/EBITDA —
BIOMARIN PHARMACEUTICAL INC (BMRN) market cap plus annual debt, less cash and eligible marketable securities.
A dated market value and complete annual debt and cash evidence are required for this bridge.
